The Next Front in Obesity: MRI Tech Redefines Muscle Health in the GLP-1 Era

MILAN, Italy – October 01, 2026 — For decades, the global pharmaceutical industry chased a single, seemingly straightforward metric: total body weight. The scale was the ultimate arbiter of success. But as the dust settles on the GLP-1 receptor agonist revolution, a more complex and urgent structural challenge has emerged. The marketplace is no longer simply asking how much weight a patient can lose, but rather, what exactly is being lost.

Today, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, that question took center stage. AMRA Medical, a Swedish health informatics company pioneering MRI-based body composition analysis, presented compelling new data that could fundamentally alter how biopharma companies design clinical trials. Their research, presented by Chief Scientific Officer Dr. Jennifer Linge, highlights a critical pivot in metabolic medicine: the urgent need to preserve functional muscle quality during pharmacologically induced weight loss.

The presentation, part of a dedicated symposium on the trevogrumab COURAGE study, underscores a growing realization among industry leaders. As the obesity treatment landscape matures, competitive advantage will belong to the companies that can optimize body composition, not just shrink it.

The Lean Mass Conundrum

The explosive commercial success of GLP-1 therapies like semaglutide has undeniably disrupted the global health sector, offering unprecedented weight loss results that rival bariatric surgery. However, this pharmacological triumph carries a hidden structural cost. Clinical data reveals that a significant proportion of the weight shed by patients on these therapies—often between 33 and 35 percent—comes from lean muscle mass rather than adipose tissue.

From a strategic perspective, this lean mass loss is a looming liability. In an aging global population, accelerated muscle depletion exacerbates the risk of sarcopenic obesity, a condition characterized by high body fat and critically low functional muscle. This can lead to increased frailty, a higher risk of falls, and a depressed resting metabolic rate, which practically guarantees weight regain if the medication is discontinued.

"The industry is realizing that melting away thirty pounds is only half the battle if a third of that loss is functional tissue," noted one clinical trial designer familiar with the shifting regulatory landscape. "The next generation of blockbuster drugs will be judged on body composition, not just BMI."

This dynamic has triggered a massive secondary gold rush in biopharma. Companies are aggressively developing adjunctive therapies—such as myostatin and activin receptor inhibitors—designed to be co-administered with GLP-1s to act as a biochemical shield for muscle tissue. But to prove these new drugs work, the industry needs a new standard of measurement.

Beyond the Scale: The Quantitative MRI Revolution

Historically, clinical trials have relied on dual-energy X-ray absorptiometry (DXA) scans and Body Mass Index (BMI) to track physical changes. While cost-effective, DXA is a blunt instrument. It often overestimates lean mass and, crucially, fails to detect subtle, microscopic changes occurring within the muscle tissue itself.

This is the precise gap AMRA Medical is exploiting. The company's proprietary technology utilizes automated analysis of quantitative MRI images to provide a forensic, three-dimensional map of a patient's body composition.

Rather than just measuring the size of a muscle, AMRA's software calculates body-size-adjusted muscle volume Z-scores alongside a critical metric: muscle fat infiltration. Also known as myosteatosis, this infiltration of adipose tissue into the muscle fibers severely degrades physical function and is independently associated with all-cause mortality.

“Body weight and lean mass does not tell us what is happening to muscle during weight loss,” said Dr. Jennifer Linge, Chief Scientific Officer at AMRA Medical. “Quantitative MRI allows us to look directly at, as well as inside, the muscle and separately measure changes in its volume and composition. This provides researchers with a deeper, and more relevant, level of information for understanding how the body responds during obesity treatment.”

The strategic implication of AMRA's technology is profound. Previous MRI research indicates that qualitative improvements in muscle composition—specifically the reduction of intramuscular fat—can occur simultaneously with reductions in total muscle volume. In other words, a patient might lose physical muscle mass, but if the fat is drained from the remaining muscle, their functional strength and metabolic health can actually improve. Without quantitative MRI, this nuanced victory is completely invisible to researchers and regulators.

The COURAGE Study and the Race for Muscle Preservation

The data presented by Dr. Linge in Milan is anchored in the Phase 2 COURAGE trial, sponsored by Regeneron Pharmaceuticals. The study is a high-stakes test of combining semaglutide with trevogrumab, a human monoclonal antibody that selectively inhibits myostatin, a protein that naturally restricts muscle growth.

Interim results from the COURAGE trial have been highly anticipated by biotech investors. The data has shown that adding trevogrumab to a GLP-1 regimen can prevent approximately half of the lean mass loss typically observed with semaglutide alone. While semaglutide monotherapy resulted in 33 percent of weight lost coming from lean muscle, the addition of low-dose trevogrumab dropped that figure to just 16.8 percent.

The trial also explored a triplet therapy, adding garetosmab (an anti-activin A antibody) to the mix, aiming to synergistically dampen muscle-wasting signals. While this aggressive approach showed even greater lean mass preservation, it was accompanied by higher discontinuation rates due to tolerability issues, highlighting the delicate biological tightrope these novel combinations must walk.

By deploying AMRA's MRI biomarkers in the COURAGE study, researchers are able to prove that the retained mass is functionally healthy tissue, not just water weight or fat-infiltrated muscle. This level of granular, FDA-cleared data is becoming essential for pharmaceutical companies looking to justify the premium pricing of combination therapies to insurers and national health systems.

A Shifting Competitive Landscape

The broader market landscape reflects this aggressive pivot toward muscle preservation. Eli Lilly's recent acquisition of Versanis—driven by the promise of bimagrumab, an activin receptor inhibitor—demonstrates the massive capital being deployed to solve the lean mass equation. Scholar Rock is similarly advancing its own myostatin inhibitor, apitegromab, in combination with tirzepatide.

However, the path to market is fraught with clinical landmines. Just last month, in September 2026, Roche abruptly abandoned the development of its anti-myostatin antibody, emugrobart, after mid-stage studies failed to show clinically meaningful efficacy. Roche's high-profile failure serves as a stark reminder to the industry: preserving muscle is biologically complex, and rudimentary imaging tools are no longer sufficient to navigate clinical development.

As the competitive focus shifts from maximum weight reduction to optimal body composition, the "picks and shovels" providers of this new gold rush—health informatics and advanced imaging companies—are experiencing a surge in strategic value. While competitors like Springbok Analytics offer AI-driven 3D visualizations of muscle health, AMRA's deep integration into global research programs like the UK Biobank and its recent "Outstanding" rating by TIME among the World's Top HealthTech Companies solidify its position as an industry standard-bearer.

The pharmaceutical industry is fundamentally rewriting the rules of metabolic medicine. The era of the bathroom scale is ending, replaced by the era of the MRI scanner. For healthcare executives, trial designers, and investors, the message from Milan is clear: the future of obesity treatment will not be measured in pounds lost, but in the quality of the tissue that remains.